Article Highlights Major Investment Points for Boston Therapeutics, Inc. (BTHE)
A recent BiotechStockTrader.com article (http://dtg.fm/SyR6), highlighting the unique and positive position that Boston Therapeutics now holds with regard to the multi-billion dollar diabetes drug industry, laid out the reasons why investors are starting to jump on board the still small biotech company. The company’s lead drug candidate, PAZ320, is the first diabetes drug to be based upon an important new technology, carbohydrate hydrolyzing enzyme inhibiting (CHEI). Unlike traditional diabetes drugs, PAZ320 doesn’t require insulin injections, and doesn’t involve interaction with important internal organs, such as the pancreas, kidneys, or liver. Instead, it is a simple chewable that operates in the…